Article

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection

2022-11-08

Abstract excerpt

<h4>Background</h4> High-grade gliomas are fatal with universally poor prognosis. Initiation of effective cancer immune responses requires functional immune cells, particularly afferent antigen-presenting cells, which are typically absent from the brain parenchyma. To overcome this limitation, two adenoviral vectors expressing HSV1-TK and Flt3L were combined to target human gliomas. This first-in-human trial asses...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 37c635df-a1fa-51bc-94e8-35d9e19c9caa
DOI: 10.1101/2022.11.04.22281950

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionDOI 10.1101/2022.11.04.22281950Read

Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trialSemantic proximity Read

Gene Therapy for High Grade Glioma: The Clinical ExperienceSemantic proximity Read

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patientsSemantic proximity Read

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem gliomaSemantic proximity Read

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaSemantic proximity Read

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitmentSemantic proximity Read

Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II)Semantic proximity Read

CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockadeSemantic proximity Read

Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up.Semantic proximity Read

Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant GliomaSemantic proximity Read

Gene Therapy for High-Grade GliomaSemantic proximity Read